Lumosa Therapeutics Co (ROCO:6535) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
71 GF Score
Price NT$90.20
GF Value NT$131.42
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

ROCO:6535
71GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$90.20 is trading 31.4% below its estimated GF Value™ of NT$131.42. GuruFocus considers Lumosa Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6535:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: NT$131.42 vs. price of NT$90.20 (31.4% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
71GF Score

Get the complete analysis for ROCO:6535

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$90.20
Price
NT$131.42
GF Value